Skip to main content
Premium Trial:

Request an Annual Quote

Personal Genome Diagnostics, Illumina Ink Cancer IVD Partnership

NEW YORK (GenomeWeb) – Personal Genome Diagnostics announced today that it has partnered with Illumina to develop two in vitro cancer diagnostics.

According to PGDx, the tests will be designed to detect and characterize tumor DNA from tissue or plasma samples, and will run on Illumina's sequencing instruments. Additional terms of the deal were not disclosed.

"PGDx currently offers advanced genomic testing services to researchers, drug developers, and physicians and patients through our CLIA-certified laboratory," CEO Doug Ward said in a statement. "We now want to apply our expertise to the development of IVD test kits for both tissue and plasma-based samples that will enable other laboratories with next-generation sequencing capability to benefit from our broad experience in cancer genomic testing."